Abstract:Purpose of review A growing number of gene therapies are getting FDA-approved for pediatric rare disorders to treat once incurable diseases. Opportunities for preventing lifetime illness and improving quality of life for these patients is now becoming a reality. Challenges exist in navigating the complexities of determining which patients will benefit from these new gene therapies and how to effectively deliver them as a standard of care. Recent findings Gene therapies have been approved for pediatric hematological, neuromuscular, cancer, and other disorders that have improved the quality of life for rare disease patients. FDA approval of these drugs has been on a case-by-case basis leading towards gaps in drug approval, physician and patient knowledge of new gene therapies, and ultimate delivery of these drugs. Identifying patients that would benefit from these drugs and other coordination of care issues have arisen with each unique gene therapy product. These gene therapies have unique requirements and patient indications that require a knowledgeable group of physicians and hospital administrators to incorporate their use as a standard of care. With more gene therapies on the near horizon for FDA approval, multidisciplinary teams may improve patient access to these drugs by streamlining approaches towards adapting gene therapies into clinical use. Summary The rapid increase in the number of FDA-approved gene therapies has not only created a number of challenges but also opportunities to improve the lives of pediatric patients with rare disorders. The adaptability of physicians, hospitals, and governmental regulatory boards is essential for delivering these new gene therapies safely and efficiently to these rare disease patients. Challenges still remain as to future requirements for additional gene therapy dosing and how to best manage financial burdens placed on the patient and providing institution.

The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases

Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience

Improving access to gene therapy for rare diseases

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

Clinical development on the frontier: gene therapy for duchenne muscular dystrophy

Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy

Riding the gene therapy wave: challenges and opportunities for rare disease patients and clinicians

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

The clinical landscape for AAV gene therapies

Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies

From unique challenges to inspired solutions: how vector engineering makes in vivo gene therapy possible

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases

A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases

Successes and challenges in clinical gene therapy

Engineering adeno-associated virus vectors for gene therapy

Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders

A Novel Small NPC1 Promoter Enhances AAV-Mediated Gene Therapy in Mouse Models of Niemann–Pick Type C1 Disease

Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord